This article is more than 5 years old. Information may no longer be current.
Survival in epithelial ovarian cancer differed by BRCA mutation type
Click Here to Manage Email Alerts
Women with epithelial ovarian cancer who carry the BRCA2 mutation experienced longer PFS, OS and treatment-free intervals than women who carry the BRCA1 mutation, according to results of a nationwide study.
Researchers conducted the trial to determine whether the mutations were associated with differences in primary treatment response, PFS, treatment-free interval and OS in epithelial ovarian cancer.
The cohort included 245 women with BRCA1 mutations and 99 women with BRCA2 mutations. Histology, tumor grade and International Federation of Gynecology and Obstetrics (FIGO) stage were comparable between the two groups. The patients who carried BRCA1 mutations were slightly younger (mean age, 51 years vs. 55 years).
Primary treatment included chemotherapy.
Researchers reported similar complete response rates between the two groups: 86% of BRCA1 mutation carriers vs. 90% of BRCA2 mutation carriers.
Women with BRCA2-associated epithelial ovarian cancer experienced longer median PFS (3.9 years vs. 2.2 years; P=.006) and median OS (9.7 years vs. 6 years; P=.04). Researchers also reported significantly longer treatment-free intervals among women with BRCA2 mutations (median 2.8 years vs. 1.7 years; P=.009).
"[The] differences could not be explained by age at diagnosis, FIGO stage or type of treatment," the researchers wrote.
Click Here to Manage Email Alerts